Patient and public involvement and engagement means that “activities and research are carried out ‘with’ or ‘by’ members of the public or patients, rather than ‘to’, ‘about’ or ‘for’ them”[1].…
One of the wins to come out of the recent NICE methods review, according to Industry and others in the Life Sciences ecosystem, was the introduction of the severity modifier.[i]…
A new Innovative Medicines Fund (IMF), the NHS England consultation on which closed last Friday, has the potential to make a meaningful impact on patient access to innovative, new medicines in England…
Last week saw the first hints of the new Health Secretary’s approach to an NHS increasingly used to setting its own agenda. Like so many other public services, political management of the…
NICE’s 187-page draft programme manual, published today for consultation, has more than enough by way of reform to HTA methods and processes for any market access aficionado to get their…
“Life Sciences will be one of the great drivers of growth in the twenty first century.” The first sentence of the foreword to the British Government’s new Life Sciences Vision…
The entrance of biosimilar competitors into a therapeutic area is an ever-present concern for pharmaceutical companies managing ageing product portfolios. On the other hand, any potential benefit to patients and…
The government has this week published the long-awaited draft data strategy: Data saves lives: reshaping health and social care with data. This new strategy builds upon previous attemptsto harness the NHS’s rich store of patient…